These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 26402177)

  • 1. [Colorectal cancer: prevention and early detection].
    Kolligs FT
    Dtsch Med Wochenschr; 2015 Sep; 140(19):1425-30. PubMed ID: 26402177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Controversies in colorectal cancer screening.
    Pox CP
    Digestion; 2014; 89(4):274-81. PubMed ID: 25034478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population.
    Imperiale TF; Ransohoff DF; Itzkowitz SH; Turnbull BA; Ross ME;
    N Engl J Med; 2004 Dec; 351(26):2704-14. PubMed ID: 15616205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sex differences in performance of fecal occult blood testing.
    Brenner H; Haug U; Hundt S
    Am J Gastroenterol; 2010 Nov; 105(11):2457-64. PubMed ID: 20700114
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics.
    Allison JE; Sakoda LC; Levin TR; Tucker JP; Tekawa IS; Cuff T; Pauly MP; Shlager L; Palitz AM; Zhao WK; Schwartz JS; Ransohoff DF; Selby JV
    J Natl Cancer Inst; 2007 Oct; 99(19):1462-70. PubMed ID: 17895475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Screening for colorectal cancer: recommendations].
    Vonlaufen A; Troillet FX; Armenian B
    Rev Med Suisse; 2013 Apr; 9(381):754-7. PubMed ID: 23659152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Faecal immunochemical tests versus guaiac faecal occult blood tests: what clinicians and colorectal cancer screening programme organisers need to know.
    Tinmouth J; Lansdorp-Vogelaar I; Allison JE
    Gut; 2015 Aug; 64(8):1327-37. PubMed ID: 26041750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lower risk of advanced neoplasia among patients with a previous negative result from a fecal test for colorectal cancer.
    Denters MJ; Deutekom M; Bossuyt PM; Stroobants AK; Fockens P; Dekker E
    Gastroenterology; 2012 Mar; 142(3):497-504. PubMed ID: 22108194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of a brush-sampling fecal immunochemical test for hemoglobin with a sensitive guaiac-based fecal occult blood test in detection of colorectal neoplasia.
    Smith A; Young GP; Cole SR; Bampton P
    Cancer; 2006 Nov; 107(9):2152-9. PubMed ID: 16998938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Colon cancer screening in 2010: an up-date.
    Weizman AV; Nguyen GC
    Minerva Gastroenterol Dietol; 2010 Jun; 56(2):181-8. PubMed ID: 20485255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostics and Epidemiology of Colorectal Cancer.
    Kolligs FT
    Visc Med; 2016 Jun; 32(3):158-64. PubMed ID: 27493942
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A New-Generation Fecal Immunochemical Test (FIT) Is Superior to Quaiac-based Test in Detecting Colorectal Neoplasia Among Colonoscopy Referral Patients.
    Vasilyev S; Smirnova E; Popov D; Semenov A; Eklund C; Hendolin P; Paloheimo L; Syrjänen K
    Anticancer Res; 2015 May; 35(5):2873-80. PubMed ID: 25964570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic performance of guaiac-based fecal occult blood test in routine screening: state-wide analysis from Bavaria, Germany.
    Brenner H; Hoffmeister M; Birkner B; Stock C
    Am J Gastroenterol; 2014 Mar; 109(3):427-35. PubMed ID: 24343548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Chemical or immunological tests for the detection of fecal occult blood in colorectal cancer screening?].
    Quintero E
    Gastroenterol Hepatol; 2009 Oct; 32(8):565-76. PubMed ID: 19577340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Detection of colorectal findings for cancer prevention by immunochemical stool test with different sensitivity levels].
    Brenner G; Faure H; Heuer S; Reinholz J
    Z Gastroenterol; 2012 Oct; 50(10):1083-8. PubMed ID: 23059801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk stratification for advanced colorectal neoplasia according to fecal hemoglobin concentration in a colorectal cancer screening program.
    Auge JM; Pellise M; Escudero JM; Hernandez C; Andreu M; Grau J; Buron A; López-Cerón M; Bessa X; Serradesanferm A; Piracés M; Macià F; Guayta R; Filella X; Molina R; Jimenez W; Castells A;
    Gastroenterology; 2014 Sep; 147(3):628-636.e1. PubMed ID: 24937264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. One-time screening for colorectal cancer with combined fecal occult-blood testing and examination of the distal colon.
    Lieberman DA; Weiss DG;
    N Engl J Med; 2001 Aug; 345(8):555-60. PubMed ID: 11529208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population.
    van Rossum LG; van Rijn AF; Laheij RJ; van Oijen MG; Fockens P; van Krieken HH; Verbeek AL; Jansen JB; Dekker E
    Gastroenterology; 2008 Jul; 135(1):82-90. PubMed ID: 18482589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of guaiac-based and quantitative immunochemical fecal occult blood testing in a population at average risk undergoing colorectal cancer screening.
    Park DI; Ryu S; Kim YH; Lee SH; Lee CK; Eun CS; Han DS
    Am J Gastroenterol; 2010 Sep; 105(9):2017-25. PubMed ID: 20502450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fecal occult blood testing.
    Sanford KW; McPherson RA
    Clin Lab Med; 2009 Sep; 29(3):523-41. PubMed ID: 19840685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.